Application value of CT radiomic nomogram in predicting T790M mutation of lung adenocarcinoma

被引:3
|
作者
Li, Xiumei [1 ]
Chen, Jianwei [2 ]
Zhang, Chengxiu [3 ]
Han, Zewen [1 ]
Zheng, Xiuying [1 ]
Cao, Dairong [1 ,4 ,5 ,6 ]
机构
[1] Fujian Med Univ, Affiliated Hosp 1, Dept Anesthesiol, Fuzhou 350005, Fujian, Peoples R China
[2] Fujian Prov Canc Hosp, Dept Pathol, Fuzhou 350014, Fujian, Peoples R China
[3] East China Normal Univ, Sch Phys & Elect Sci, Shanghai Key Lab Magnet Resonance, Shanghai 200062, Peoples R China
[4] Fujian Med Univ, Affiliated Hosp 1, Natl Reg Med Ctr, Dept Radiol, Binhai Campus, Fuzhou 350212, Fujian, Peoples R China
[5] Fujian Med Univ, Affiliated Hosp 1, Fujian Key Lab Precis Med Canc, Fuzhou 350005, Fujian, Peoples R China
[6] Fujian Med Univ, Affiliated Hosp 1, Key Lab Radiat Biol, Fujian Higher Educ Inst, Fuzhou 200062, Peoples R China
关键词
Lung adenocarcinoma; Radiomics; Computed tomography; T790M; CANCER;
D O I
10.1186/s12890-023-02609-y
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
BackgroundThe purpose of this study was to develop a radiomic nomogram to predict T790M mutation of lung adenocarcinoma base on non-enhanced CT lung images.MethodsThis retrospective study reviewed demographic data and lung CT images of 215 lung adenocarcinoma patients with T790M gene test results. 215 patients (including 52 positive) were divided into a training set (n = 150, 36 positive) and an independent test set (n = 65, 16 positive). Multivariate logistic regression was used to select demographic data and CT semantic features to build clinical model. We extracted quantitative features from the volume of interest (VOI) of the lesion, and developed the radiomic model with different feature selection algorithms and classifiers. The models were trained by a 5-fold cross validation strategy on the training set and assessed on the test set. ROC was used to estimate the performance of the clinical model, radiomic model, and merged nomogram.ResultsThree demographic features (gender, smoking, emphysema) and ten radiomic features (Kruskal-Wallis as selection algorithm, LASSO Logistic Regression as classifier) were determined to build the models. The AUC of the clinical model, radiomic model, and nomogram in the test set were 0.742(95%CI, 0.619-0.843), 0.810(95%CI, 0.696-0.907), 0.841(95%CI, 0.743-0.938), respectively. The predictive efficacy of the nomogram was better than the clinical model (p = 0.042). The nomogram predicted T790M mutation with cutoff value was 0.69 and the score was above 130.ConclusionThe nomogram developed in this study is a non-invasive, convenient, and economical method for predicting T790M mutation of lung adenocarcinoma, which has a good prospect for clinical application.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Application value of CT radiomic nomogram in predicting T790M mutation of lung adenocarcinoma
    Xiumei Li
    Jianwei Chen
    Chengxiu Zhang
    Zewen Han
    Xiuying zheng
    Dairong Cao
    BMC Pulmonary Medicine, 23
  • [2] Genomic Evolution in a Patient With Lung Adenocarcinoma With a Germline EGFR T790M Mutation
    Maekinen, Netta
    Zhou, Meng
    Bemus, Meredith
    Nevin, Julius
    Nag, Anwesha
    Chen, Ruthia
    Colson, Yolonda L.
    Thorner, Aaron R.
    Oxnard, Geoffrey R.
    Meyerson, Matthew
    Sholl, Lynette M.
    JTO CLINICAL AND RESEARCH REPORTS, 2021, 2 (04):
  • [3] Clinical Impact of Pretreatment EGFR T790M Mutation in Lung Adenocarcinoma Patients
    Macerola, Elisabetta
    Bruno, Rossella
    Prediletto, Irene
    Sensi, Elisa
    Chella, Antonio
    Landi, Lorenza
    Ali, Greta
    Fontanini, Gabriella
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1207 - S1207
  • [4] Effects of vandetanib on lung adenocarcinoma cells harboring an EGFR T790M mutation in vivo
    Ichihara, Eiki
    Ohashi, Kadoaki
    Takigawa, Nagio
    Osawa, Masahiro
    Takeda, Hiromasa
    Ochi, Nobuaki
    Harada, Daijiro
    Yasugi, Masayuki
    Tanimoto, Mitsune
    Kiura, Katsuyuki
    CANCER RESEARCH, 2009, 69
  • [5] T790M: A Favorable Mutation?
    Lan, Shen
    Jian, Hong
    Yu, Yongfeng
    Lu, Shun
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1205 - S1205
  • [7] Successful osimertinib treatment for leptomeningeal carcinomatosis from lung adenocarcinoma with the T790M mutation of EGFR
    Sakai, Hitomi
    Hayashi, Hidetoshi
    Iwasa, Tsutomu
    Hasegawa, Yoshikazu
    Takeda, Masayuki
    Nakagawa, Kazuhiko
    ESMO OPEN, 2017, 2
  • [8] Lung Adenocarcinoma with Double Heterozygote EGFR mutation and Combined Resistance: ALK Translocation and EGFR T790M
    Denninghoff, V.
    Wainsztein, V.
    Cuello, M. T.
    Recondo, G.
    Rojas Bilbao, E.
    Avagnina, A.
    Recondo, G.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : S179 - S179
  • [9] Lung adenocarcinoma with good response to erlotinib after gefitinib treatment failure and acquired T790M mutation
    Wu, Shang-Gin
    Shih, Jin-Yuan
    Yu, Chong-Jen
    Yang, Pan-Chyr
    JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (04) : 451 - 452
  • [10] A novel radiomic nomogram for predicting epidermal growth factor receptor mutation in peripheral lung adenocarcinoma
    Lu, Xiaoqian
    Li, Mingyang
    Zhang, Huimao
    Hua, Shucheng
    Meng, Fanyang
    Yang, Hualin
    Li, Xueyan
    Cao, Dianbo
    PHYSICS IN MEDICINE AND BIOLOGY, 2020, 65 (05):